NEW YORK (TheStreet) -- Roche Holding Ltd.
(RHHBY) will pay up to $1.725 billion to buy Seragon Pharmaceuticals, a privately-held, San Diego-based biotech company that researches breast cancer treatments, Reuters reports.
The company was spun out from Aragon Pharmaceuticals in 2013 when that company was bought by Johnson & Johnson
(JNJ - Get Report), Reuters noted.
Roche Holding shares closed slightly lower at $37.29 yesterday.
Must Read: Warren Buffett's 25 Favorite Growth Stocks
RHHBY data by YCharts
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.